Patient Voice

675  Appropriate Use of Opioids in Patients with Kidney Diseases  
David M. White  
See related article on page 746.

Editorials

677  Long-Term Consequences of Acute Kidney Injury in Children  
Scott M. Sutherland  
See related article on page 685.

679  Antimalarial Drugs for the Prevention of Chronic Kidney Disease in Patients with Rheumatoid Arthritis: The Importance of Controlling Chronic Inflammation?  
Jennifer C. Rodrigues and Joanne M. Bargman  
See related article on page 702.

681  Does the Kidney Biopsy Portend the Future of Nephrology?  
Scott J. Gilbert  
See related article on page 718.

683  Is There a Need for Additional DQ Matching?  
Caner Süsal and Martin Zeier  
See related article on page 763.

Original Articles

Acute Kidney Injury and ICU Nephrology

685  Healthcare Utilization after Acute Kidney Injury in the Pediatric Intensive Care Unit  
Erin Hessey, Geneviève Morissette, Jacques Lacroix, Sylvie Perreault, Susan Samuel, Marc Dorais, Véronique Phan, Philippe Jouvet, Jean-Philippe Latrance, Jacques LeLorier, Ana Falijan, Michael Pizzi, Louise Roy, and Michael Zappitelli  
See related editorial on page 677.

Chronic Kidney Disease

693  Time-Centered Approach to Understanding Risk Factors for the Progression of CKD  
Elaine Ku, Kirsten L. Johansen, and Charles E. McCulloch

702  Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis  
Chia-Lin Wu, Chia-Chu Chang, Chew-Teng Kor, Tao-Hsiang Yang, Ping-Fang Chiu, Der-Cherng Tarng, and Chih-Cheng Hsu  
See related editorial on page 679.

Clinical Nephrology

710  Performance on the Nephrology In-Training Examination and ABIM Nephrology Certification Examination Outcomes  
Daniel Jurich, Lauren M. Duhigg, Troy J. Plumb, Steven A. Haist, Janine L. Hawley, Rebecca S. Lipner, Laurel Smith, and Suzanne M. Norby
Clinical Nephrology
718 Survey of Kidney Biopsy Clinical Practice and Training in the United States
Christina M. Yuan, Robert Nee, Dustin J. Little, Rajeev Narayan, John M. Childs, Lisa K. Prince, Rajeev Raghavan, and James D. Oliver III for the Nephrology Education Research and Development Consortium (NERDC)
See related editorial on page 681.

Diabetes and the Kidney
727 Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study
Emily B. Schroeder, Michel Chonchol, Susan M. Shetterly, J. David Powers, John L. Adams, Julie A. Smittdiehl, Gregory A. Nichols, Patrick J. O’Connor, and John F. Steiner

Maintenance Dialysis
735 Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study
Jennifer E. Flythe, Tandrea Hilliard, Graciela Castillo, Kourtney Ikeler, Jazmine Orazi, Emaad Abdel-Rahman, Amy Barton Pai, Matthew B. Rivara, Wendy L. St. Peter, Steven D. Weisbord, Caroline Wilkie, and Rajnish Mehrotra

746 Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients
Julie H. Ishida, Charles E. McCulloch, Michael A. Steinman, Barbara A. Grimes, and Kirsten L. Johansen
See related Patient Voice on page 675.

Transplantation
755 Secular Trends in Infection-Related Mortality after Kidney Transplantation
Susanna Kinnunen, Pauli Karhapää, Auni Juutilainen, Patrik Finne, and Ilkka Helanterä

763 HLA-DQ Mismatching and Kidney Transplant Outcomes
Napat Leeaphorn, Jeremy Ryan A. Pena, Natanong Thamcharoen, Eliyahu V. Khankin, Martha Pavlakis, and Francesca Cardarelli
See related editorial on page 683.

772 Awareness of Racial Disparities in Kidney Transplantation among Health Care Providers in Dialysis Facilities
Joyce J. Kim, Mohua Basu, Laura Plantinga, Stephen O. Pastan, Sumit Mohan, Kayla Smith, Taylor Melanson, Cam Escoffery, and Rachel E. Patzer

Research Letter
782 The Effect of Learning Styles on Adverse Events in Home Hemodialysis Patients
Bourne L. Auguste, Abdullah Al-Muhaiteeb, and Christopher T. Chan

Kidney Case Conference: How I Treat
784 Management of Membranous Nephropathy in the PLA2R Era
Andrew S. Bomback

Kidney Case Conference: Nephrology Quiz and Questionnaire
787 Management of Severe Hyponatremia with Continuous Renal Replacement Therapies
Mitchell H. Rosner and Michael J. Connor Jr.

Perspectives
790 Protecting Donors and Safeguarding Altruism in the United States: The Living Donor Protection Act
Alexander C. Wiseman

793 Treatment Choices for Hepatitis C in Patients with Kidney Disease
Fabrizio Fabrizi and Piergiorgio Messa

796 Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know
Kenar D. Jhaveri and Mitchell H. Rosner
On the Cover

What’s the diagnosis?

We report the case of a 59-year-old woman with end-stage renal disease secondary to diabetic nephropathy, status post a deceased donor kidney transplant. One year after transplant, she presented with generalized weakness. Laboratory work-up revealed a serum creatinine of 9.3 mg/dL (baseline 1.4 mg/dL), with mild hematuria. Urine protein/creatinine ratio was 0.05 g/g. Twelve-hour tacrolimus trough level was 7.2 ng/mL. Serology workup including BK virus, adenovirus, EBV, Cytomegalovirus, antinuclear antibody, antineutrophil cytoplasmic antibodies, and anti-glomerular basement membrane antibody were negative. CT of the abdomen and brain were unremarkable. An allograft kidney biopsy confirmed the diagnosis of polyomavirus-associated nephropathy. Given her undetectable BK, serum JC viral load was checked and noticed markedly elevated at 22,900 copies/ml. Mycophenolate Mofetil dose was reduced to 250 mg twice a day from 1000 mg twice a day and her Tacrolimus dose was also reduced to Tacrolimus goal of 3-5 ng/mL. Her JC virus became undetected and serum creatinine returned to 1.6 mg/dL and remained stable at that range.

Imaging demonstrated diffuse interstitial inflammation along with enlarged tubules’ nuclei which consist of viral cytopathic changes (left and right panel). Immunostain for polyomavirus (SV40 large-T antigen) showed numerous tubular cell nuclei with positive staining (central panel).

JC virus is one of the polyomavirus family. It is an uncommon opportunistic infection seen in kidney transplant recipients. Clinical manifestations can include neurologic symptoms (progressive multifocal leukoencephalopathy) and/or allograft kidney dysfunction. A kidney biopsy along with serology are necessary for definitive diagnosis. Treatment is a reduction of immunosuppression.

(Images and text provided by Mohamad Hanouneh, MD, Nada Alachkar, MD, and Sami Alasfar, MD, Johns Hopkins University, Department of Medicine, Division of Nephrology, Baltimore, Maryland)